Axel Lechner
Overview
Explore the profile of Axel Lechner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thelen M, Wennhold K, Lehmann J, Garcia-Marquez M, Klein S, Kochen E, et al.
NPJ Precis Oncol
. 2021 Jun;
5(1):52.
PMID: 34135436
The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by...
12.
Sturmer S, Lechner A, Berking C
J Immunother
. 2021 Mar;
44(5):193-197.
PMID: 33734141
Immune-related adverse events have been described in 86%-96% of high-risk melanoma patients treated with immune checkpoint inhibitors (ICI), while in 17%-59% of cases these are classified as severe or even...
13.
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
Leuchte K, Staib E, Thelen M, Godel P, Lechner A, Zentis P, et al.
Cancer Immunol Immunother
. 2020 Oct;
70(4):893-907.
PMID: 33006650
Thermal ablative therapies are standard treatments for localized hepatocellular carcinoma (HCC). In addition to local tumor destruction, ablation leads to abscopal effects in distant lesions most likely mediated by an...
14.
Lechner A, Schlosser H, Thelen M, Wennhold K, Rothschild S, Gilles R, et al.
Oncoimmunology
. 2019 Feb;
8(3):1535293.
PMID: 30723574
B lymphocytes are important players in immune responses to cancer. However, their composition and function in head and neck squamous cell carcinoma (HNSCC) has not been well described. Here, we...
15.
Schlosser H, Thelen M, Lechner A, Wennhold K, Garcia-Marquez M, Rothschild S, et al.
Oncoimmunology
. 2018 Dec;
8(1):e1512458.
PMID: 30546950
Tumor-infiltrating lymphocytes (TILs) are correlated to prognosis of several kinds of cancer. Most studies focused on T cells, while the role of tumor-associated B cells (TABs) has only recently gained...
16.
Thelen M, Lechner A, Wennhold K, von Bergwelt-Baildon M, Schlosser H
Cancer Res
. 2018 Aug;
78(17):5173-5174.
PMID: 30115699
No abstract available.
17.
Rothschild U, Muller L, Lechner A, Schlosser H, Beutner D, Laubli H, et al.
Swiss Med Wkly
. 2018 May;
148:w14625.
PMID: 29756633
Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour arising from multiple anatomical subsites in the head and neck region. The treatment for early-stage disease is generally single...
18.
Hufbauer M, Maltseva M, Meinrath J, Lechner A, Beutner D, Huebbers C, et al.
Int J Cancer
. 2018 Apr;
143(6):1426-1439.
PMID: 29663357
Human papillomavirus type 16 (HPV16) is a major risk for development of oropharyngeal squamous-cell-carcinoma (OPSCC). Although HPV OPSCC metastasize faster than HPV tumors, they have a better prognosis. The molecular...
19.
Wennhold K, Thelen M, Schlosser H, Haustein N, Reuter S, Garcia-Marquez M, et al.
Cancer Immunol Res
. 2017 Aug;
5(9):730-743.
PMID: 28778961
Cancer immunotherapy by therapeutic activation of T cells has demonstrated clinical potential. Approaches include checkpoint inhibitors and chimeric antigen receptor T cells. Here, we report the development of an alternative...
20.
Lechner A, Schlosser H, Rothschild S, Thelen M, Reuter S, Zentis P, et al.
Oncotarget
. 2017 Jun;
8(27):44418-44433.
PMID: 28574843
The composition of tumor-infiltrating lymphocytes (TIL) reflects biology and immunogenicity of cancer. Here, we characterize T-cell subsets and expression of immune checkpoint molecules in head and neck squamous cell carcinoma...